Cirrhotic ascites is driven by proximal tubular sodium reabsorption, mainly via NHE3. Due to spatial coupling of NHE3 and SGLT2, SGLT2 inhibitors reduce NHE3 activity. Early clinical data (case reports, pilot RCTs) suggest benefits in ascites control, but sample sizes are small. This review covers mechanisms and emerging evidence for SGLT2 inhibitors in cirrhotic ascites.
Introduction
In cirrhosis, portal hypertension and arterial under‑filling activate RAAS and sympathetic nerves, increasing proximal sodium reabsorption. This causes ascites and diuretic resistance. NHE3 is the key proximal transporter. SGLT2 colocalizes with NHE3, providing a rationale for SGLT2 inhibition.
Limitations of Conventional Diuretics
Loop diuretics inhibit NKCC2, reduce macula densa NaCl sensing, stimulate renin, and upregulate distal transporters (NCC, ENaC), causing "braking phenomenon." Proximal reabsorption remains elevated.
Molecular Basis of SGLT2i Natriuresis
SGLT2 directly reabsorbs only 3‑5% of sodium, but its inhibition suppresses NHE3 via the SGLT2–MAP17–NHE3 microdomain, diverting >7% of filtered sodium distally. This effect is context‑dependent; distal compensation (NCC upregulation) may occur.
Neuronal and Tissue Effects
Increased distal chloride delivery enhances tubuloglomerular feedback and suppresses renin. SGLT2 inhibitors also reduce sympathetic nerve activity. In heart failure and CKD, they mobilize non‑osmotic sodium from skin/fascia (²³Na MRI data in cirrhosis lacking).
Clinical Evidence
Case reports and pilot RCTs show reduced ascites, fewer paracenteses, and improved natriuresis. A real‑world analysis (∼10,000 patients) reported 32% fewer severe hepatic outcomes and 46% fewer paracenteses. Most evidence is level III‑IV; large RCTs are needed.
Safety
Large trials (EMPA‑REG, EMPEROR, EMPA‑KIDNEY) show no increase in serious hypoglycemia, UTIs, or hepatotoxicity vs placebo. Genital mycotic infections increase modestly. Cirrhosis‑specific risks (SBP, encephalopathy) are understudied. SGLT2 inhibitors do not worsen hyponatremia; hypotension risk requires monitoring.
Future Directions
Priorities: mechanistic studies of NHE3 coupling, ²³Na MRI for tissue sodium, development of "natriuretic‑biased" agents, biomarker validation (urinary chloride, exosomal pNHE3), and multicenter RCTs with clinical endpoints.
Conclusions
SGLT2 inhibitors attenuate proximal tubular sodium reabsorption through a proximal microdomain comprising SGLT2, MAP17, and NHE3. Downstream effects include modulation of the RAAS and sympathetic nervous system, potentially redistributing tissue sodium. These mechanisms directly address the low distal sodium delivery that underlies diuretic resistance in cirrhotic ascites. Early clinical observations indicate promising effects on natriuresis and reductions in ascites burden, with a safety profile consistent with experience from other trials involving SGLT2 inhibitors. Although the current evidence remains preliminary and limited, a coherent translational pathway from "mechanistic rationality" to "clinical feasibility" has been initially established, providing a solid basis for subsequent high-quality clinical validation.
Full text
https://www.xiahepublishing.com/2310-8819/JCTH-2025-00465
The study was recently published in the Journal of Clinical and Translational Hepatology .
The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study's novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.
